SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934*

 

 

Ohr Pharmaceutical, Inc.

 

(Name of Issuer)

 

 

Common Stock

 

(Title of Class of Securities)

 

 

67778H200

 

(CUSIP Number)

     

 

 

March 19, 2014

 

(Date of Event Which Requires Filing of This Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  Rule 13d-1(b)  
  Rule 13d-1(c)  
  Rule 13d-1(d)  

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
 

  

CUSIP No. 67778H200 SCHEDULE 13G

 

 

 

1

NAMES OF REPORTING PERSONS

Shalom Hirschman

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER

1,468,765

  6

SHARED VOTING POWER

0

  7

SOLE DISPOSITIVE POWER

1,468765

  8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

1,468,765

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.3%1

12

TYPE OF REPORTING PERSON

IN

       

1. Based on 19,970,049 shares of Common Stock of the Company outstanding at the close of business on December 27, 2013, as represented in the Company's Annual Report on Form 10-K for the Year ended September 30, 2013.

 

 
 

 

Item 1(a) Name of Issuer :
   
  Ohr Pharmaceutical, Inc.
   
   
Item 1(b) Address of Issuer’s Principal Executive Offices :
   
 

800 3rd Ave, 11th Floor

New York, NY 10022

   
   
Items 2(a) Name of Person Filing :
   
  This Schedule 13G is being filed by Shalom Hirschman.
   
   
Item 2(b) Address of Principal Business Office :
   
 

5240 Blackstone Avenue

Bronx, NY 10471

   
   
Item 2(c) Citizenship :
   
  US
   
   
Item 2(d) Title of Class of Securities :
   
  Common Stock
   
   
Item 2(e) CUSIP Number :
   
 

67778H200

 

 

 
 

 

Item 3   If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a :  
         
  (a)   Broker or dealer registered under Section 15 of the Act;  
         
  (b)   Bank as defined in Section 3(a)(6) of the Act;  
         
  (c)    Insurance company as defined in Section 3(a)(19) of the Act;  
         
  (d)   Investment company registered under Section 8 of the Investment Company Act of 1940;  
         
  (e)   An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);  
         
  (f)   An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);  
         
  (g)   A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);  
         
  (h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);  
         
  (i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;  
         
  (j)   A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);  
         
  (k)   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).  
         
         

 

 
 

 

  Item 4 Ownership :
   
  The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page hereto and is incorporated herein by reference.
 

 

☐X

   
   
Item 5  Ownership of Five Percent or Less of a Class :
   
  If this statement is being filed to report the fact that as of the date hereof the Select Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:
 

 

   
   
Item 6  Ownership of More than Five Percent on Behalf of Another Person :
 

 

N/A

   
   
Item 7  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company :
 

 

N/A

   
   
Item 8 Identification and Classification of Members of the Group :
 

 

N/A

   
   
Item 9 Notice of Dissolution of Group :
 
N/A
   

 

 
 

  

   
Item 10 Certification :

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

       
    By: /s/ Shalom Hirschman  
    Name: Shalom Hirschman

 

 

 

 

       

Dated: March 21, 2014